The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States.

Autor: Slater RL; BresMed Health Solutions Ltd, Sheffield, UK., Lai Y; Merck & Co, Inc, Kenilworth, NJ, USA., Zhong Y; Merck & Co, Inc, Kenilworth, NJ, USA., Li H; Merck & Co, Inc, Kenilworth, NJ, USA., Meng Y; BresMed Health Solutions Ltd, Sheffield, UK., Moreno BH; Merck & Co, Inc, Kenilworth, NJ, USA., Godwin JL; Merck & Co, Inc, Kenilworth, NJ, USA., Frenkl T; Merck & Co, Inc, Kenilworth, NJ, USA., Sonpavde GP; Dana-Farber Cancer Institute, Boston, MA, USA., Mamtani R; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.

Publikováno v: Journal of medical economics [J Med Econ] 2020 Sep; Vol. 23 (9), pp. 967-977. Date of Electronic Publication: 2020 Jun 12.

Eimeria bovis: development in calves treated with thiamine metabolic antagonist (amprolium) in feed.

Autor: Slater RL, Hammond DM, Miner ML

Publikováno v: Transactions of the American Microscopical Society [Trans Am Microsc Soc] 1970 Jan; Vol. 89 (1), pp. 55-65.